STATEMENT OF NEED
Diabetes is an increasing pandemic event affecting 25.8 million people in the United States (US), or 8.3% of the population.1 Of these, 18.8 million people have been diagnosed, while approximately 7 million people remain undiagnosed, and therefore untreated. Despite advances in diabetes treatments and proven benefits of achieving tight glycemic control, 37% of the population with diagnosed diabetes remain uncontrolled (A1C<7%).2-5
Several reasons have been cited as possible explanations for the large percentage of patients with diabetes that remain uncontrolled, including failure to treat aggressively, lack of patient adherence, and lack of patient motivation.3,6 Advances in understanding the pathophysiology of diabetes has led to recommendations for the earlier use of insulin due to the natural physiologic nature of insulin, rapid onset of action, superior efficacy, no dose limits, improvements on lipid profiles, and its effectiveness in achieving glycemic goals.2,3,7,8 However, there is commonly a delay or lack of intensification of insulin due to reluctance from healthcare professionals and patients.9-11 Primary care clinicians need to be acutely aware of the proposed barriers to achieving tight glycemic control and strategies to overcome them in order to have a positive influence and increase glycemic control in their patients.
1Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. 2Nathan DM, et al. Diabetes Care. 2009. 3American Diabetes Association. Diabetes Care. 2012. 4Stratton IM, et al. BMJ. 2000. 5Blonde L, Karter AJ. Am J Med. 2005. 6Koro CE, et al. Diabetes Care. 2004. 7Buse JB, et al. Lancet. 2009. 8Gavin JR, et al. Diabetes Educ. 2010. 9Peyrot M, et al. Diabetes Care. 2005. 10Rochester CD, et al. Am J Health-Syst Pharm. 2010. 11Karter AJ, et al. Diabetes Care. 2010.
John E. Anderson, MD (Activity Chair)
Internal Medicine Physician
The Frist Clinic
President-Elect, Medicine and Science
American Diabetes Association
Lawrence Blonde, MD, FACP, FACE
Director of the Ochsner Diabetes Clinical Research Unit
Associate Internal Medicine Residency Program Director
Ochsner Medical Center
New Orleans, LA
Bruce Bode, MD, FACE*One expert faculty will present per activity location.
Clinical Associate Professor
Department of Medicine, Emory University
Atlanta Diabetes Associates
Primary care clinicians, including physicians, physician assistants, pharmacists, nurses, nurse practitioners, certified diabetes educators, hospitalists, medical directors, and pharmacy directors, who treat patients with diabetes.
At the conclusion of this application-based activity, participants will be able to:
The activity has been reviewed and is acceptable for up to 1.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CEC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM.
Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This application-based activity has been assigned ACPE# 0245-0000-12-007-L01-P and will award 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit.
CEC complies with the Criteria for Quality for continuing education programming.
Creative Educational Concepts, Inc. (CEC) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Centerís Commission on Accreditation.
CEC provides this activity for 1.5 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
Statements of credit will be issued to those who complete a CE/CME request form and will be mailed within 10 business days.
To view more details about your city and venue location, click on the city below:
Creative Educational Concepts, Inc. (CEC) reserves the right to cancel or change dates, speakers, content, and/or other details without notice. Furthermore, CEC reserves the right to refuse service to any person at CEC's sole discretion, subject to applicable law. CEC, Lilly, and Sanofi-aventis U.S. Inc., A SANOFI COMPANY are not responsible for speakers' or participants' statements, materials, acts, or omissions not previously approved by CEC.
Dr. John Anderson practices internal medicine and diabetes at the Frist Clinic in Nashville, TN. He has been Chief of Medicine and Chair of the Board of Trustees of Centennial Medical Center, a tertiary care Hospital Corporation of America, in Nashville. He has been a long time volunteer for the American Diabetes Association (ADA), having served two separate terms on the Board of Directors, and has participated in and chaired numerous working groups and task forces. He currently serves on the Executive Committee of the ADA in his role as Vice-President, Medicine and Science.
Dr. Anderson has disclosed that he is on an advisory panel for sanofi-aventis and a member of the speakersí bureaus for Abbott, Amylin, Daiichi Sankyo, Eli Lilly, and Novo Nordisk.
Dr. Blonde is Director of the Ochsner Diabetes Clinical Research Unit in the Department of Endocrinology, Diabetes and Metabolism, and an Associate Internal Medicine Residency Program Director at the Ochsner Medical Center in New Orleans, LA. Dr. Blondeís clinical and research activities have focused on patients with diabetes mellitus and investigations of new therapies and healthcare delivery systems for them. He is a member of the Executive Committee and past Chair of the Steering Committee of the National Diabetes Education Program, a partnership of the National Institutes of Health, the Centers for Disease Control and Prevention, and more than 200 public and private organizations working to "change the way diabetes is treated."
Dr. Blonde has been a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE) and the Board of Trustees of the American College of Endocrinology (ACE). Dr. Blonde has been Chair of the American Diabetes Association (ADA) Doing Better Committee, a former member of the ADA Board of Directors and former Chair of the ADA Professional Practice Committee, which develops practice guidelines for the care of people with diabetes.
Dr. Blonde has disclosed that he is a consultant for Amylin, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Halozyme, Johnson & Johnson, MannKind Corporation, Merck, Novo Nordisk, Orexigen Therapeutics, Roche, sanofi-aventis, Santarus, and VeroScience. His clinic, Ochsner Clinic, receives grant/research support from Boehringer Ingelheim, Johnson & Johnson, Lilly, Novo Nordisk, Roche, and sanofiaventis. He is a member of the speakersí bureaus for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Merck, Novo Nordisk, Santarus, and VeroScience. Dr. Blondeís late spouseís estate contains shares of Amylin and Pfizer.
Dr. Bode is a diabetes specialist with Atlanta Diabetes Associates in Georgia, and is currently on the faculty of Emory University as a clinical associate professor in the Department of Medicine. He received his medical degree from Emory University School of Medicine in Atlanta, GA, and completed a fellowship in diabetes with Paul C. Davidson, MD, and an internship and residency at Emory University Affiliated Hospitals.
He has a strong affinity for working with children and adults afflicted with diabetes and has served on the board of directors of the Atlanta chapters of the Juvenile Diabetes Research Foundation (JDRF), the American Diabetes Association (ADA), and the Georgia diabetes camps. He is a past president of the ADA Georgia Affiliate and is editor of the ADA's 2004 edition of Medical Management of Type 1 Diabetes. He is also a member of the JDRF research team validating the efficacy and safety of real-time continuous glucose monitoring (CGM).
A prolific writer, Dr. Bode has written or contributed to several other books, including Diabetes DEK - How to Control and Manage Diabetes Mellitus and The Insulin Pump Therapy Book: Insights From the Experts. In addition, he has written or co-written numerous articles and abstracts for professional journals such as The New England Journal of Medicine, Diabetes, Diabetes Care, Diabetes Technology and Therapeutics, The Journal of New Developments in Clinical Medicine, Diabetes Metabolism Research and Reviews, and Diabetes Spectrum.
Dr. Bode has disclosed that he is a consultant for Lilly, Novo Nordisk, Sanofi, and Medtronic; receives grant/research support from Lilly, Novo Nordisk, Sanofi, Medtronic, MannKind, and Merck; and is on the speakers' bureau for Lilly, Novo Nordisk, Sanofi, Medtronic, and Merck.
|Presented by Creative Educational Concepts, Inc.||Supported by independent educational grants from|